Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy

Area of Science:

• Oncology
• Pharmacogenetics
• Drug Safety

Background:

• Molecular-targeted drugs offer precise cancer cell attack with fewer adverse drug reactions (ADRs).
• Despite their precision, these drugs can cause severe, potentially life-threatening ADRs.
• Predicting patient risk for ADRs is increasingly important for safe molecular-targeted therapy.

Purpose of the Study:

• To review current research on genetic variants and severe ADRs in molecular-targeted cancer therapy.
• To highlight the role of pharmacogenetics in understanding drug toxicity.
• To inform personalized therapeutic strategies based on genetic profiles.

Main Methods:

• Literature review of studies reporting genetic variants and molecular-targeted drug-induced severe ADRs in oncology.
• Analysis of existing data on genotype-phenotype correlations for drug toxicity.
• Synthesis of findings to provide an overview of current knowledge.

Main Results:

• Genetic variants are associated with specific severe ADRs in patients receiving molecular-targeted drugs.
• Pharmacogenetics offers insights into individual susceptibility to drug toxicity.
• The relationship between genetic profiles and ADR risk is complex and under active investigation.

Conclusions:

• Identifying genetic variants can aid in predicting patients at risk for severe ADRs.
• Pharmacogenetics is a key tool for optimizing molecular-targeted therapy selection.
• Further research is needed to fully elucidate genotype-specific ADR risks in oncology.